Clinical Trial Update: Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India [Phase 1]

View source ↗

Summary

Phase 1 open-label safety study of a three-antigen Leishmania polyprotein vaccine with MPL-SE adjuvant in healthy adults in India; the trial status is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-kala-azar Dermal Leishmaniasis
• Visceral Leishmaniasis

Drugs mentioned

• Three-Antigen Leishmania Polyprotein Vaccine with MPL-SE

Snippet

Sponsor: Access to Advanced Health Institute (AAHI) | Conditions: Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis | Phase 1 | Status: COMPLETED